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Background: The recently reported declining burden of malaria in some African countries has been attributed to
scaling-up of different interventions although in some areas, these changes started before implementation of major
interventions. This study assessed the long-term trends of malaria burden for 20 years (1992–2012) in Magoda and
for 15 years in Mpapayu village of Muheza district, north-eastern Tanzania, in relation to different interventions as
well as changing national malaria control policies.
Methods: Repeated cross-sectional surveys recruited individuals aged 0 – 19 years from the two villages whereby
blood smears were collected for detection of malaria parasites by microscopy. Prevalence of Plasmodium falciparum
infections and other indices of malaria burden (prevalence of anaemia, splenomegaly and gametocytes) were
compared across the years and between the study villages. Major interventions deployed including a mobile clinic,
bed nets and other research activities, and changes in national malaria control policies were also marked.
Results: In Magoda, the prevalence of P. falciparum infections initially decreased between 1992 and 1996 (from 83.5
to 62.0%), stabilized between 1996 and 1997, and further declined to 34.4% in 2004. A temporary increase between
2004 and 2008 was followed by a progressive decline to 7.2% in 2012, which is more than 10-fold decrease since
1992. In Mpapayu (from 1998), the highest prevalence was 81.5% in 1999 and it decreased to 25% in 2004. After a
slight increase in 2008, a steady decline followed, reaching <5% from 2011 onwards. Bed net usage was high in
both villages from 1999 to 2004 (≥88%) but it decreased between 2008 and 2012 (range, 28% - 68%). After
adjusting for the effects of bed nets, age, fever and year of study, the risk of P. falciparum infections decreased
significantly by ≥97% in both villages between 1999 and 2012 (p < 0.001). The prevalence of splenomegaly
(>40% to <1%) and gametocytes (23% to <1%) also decreased in both villages.
Discussion and conclusions: A remarkable decline in the burden of malaria occurred between 1992 and 2012 and
the initial decline (1992 – 2004) was most likely due to deployment of interventions, such as bed nets, and better
services through research activities. Apart from changes of drug policies, the steady decline observed from 2008
occurred when bed net coverage was low suggesting that other factors contributed to the most recent pattern.
These results suggest that continued monitoring is required to determine causes of the changing malaria
epidemiology and also to monitor the progress towards maintaining low malaria transmission and reaching related
millennium development goals.* Correspondence: deusishe@yahoo.com
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Malaria has been a major cause of morbidity and mortality
in tropical areas particularly in sub-Saharan Africa (SSA),
and was estimated to cause 300 – 350 million cases and
0.5 - 1 million deaths annually between 2000 and 2007 [1].
However, recent reports have shown that the burden of
malaria has declined in several countries with remarkable
differences between different regions of Africa [1,2]. In
southern Africa, a significant decline of malaria burden has
been reported in the South African Republic [3-6], Zambia
[7,8], Swaziland and Southern part of Mozambique [9,10].
A similar decline has also been reported in the Horn of
Africa (Ethiopia and Eritrea) [11-15] and in isolated islands
of Zanzibar [16,17], Sao Tome and Principe [18] and Bioko
Island in Equatorial Guinea [19,20]. Reports from other
parts of Africa show inconsistent results, although a declin-
ing burden of malaria has been reported in some countries,
including Kenya [21-24], Tanzania [25-28], Rwanda [15,29],
the Gambia [30,31] and Gabon [32]. These changes have
been attributed to scaling-up of control interventions such
as deployment of artemisinin-based combination therapy
(ACT), insecticide-treated bed nets (ITNs), indoor residual
spraying (IRS) and larval control [2,33]; yet, there are indi-
cations that the declining malaria burden in some of the
countries actually started before implementation of such
major intervention programmes [2]. A recent study con-
ducted in Kenya revealed that drivers of changing malaria
epidemiology in some areas might not be entirely attrib-
uted to claimed interventions [34].
In Tanzania, malaria has until the mid-2000s been re-
sponsible for over 18 million cases, 100,000 deaths/year
and accounting for over 43% of outpatient cases, 30% of all
hospital admissions and 40% of deaths occurring at health
facilities [35]. Despite few reports which have indicated that
malaria has declined in most parts of the country [36],
most of the data obtained from health facilities through
the health management information system (HMIS) have
revealed that the burden of malaria in Tanzania has
remained largely unchanged with high and similar propor-
tions of hospital attendances, admissions and deaths be-
tween 2003 and 2010, as documented in the World Health
Organization (WHO) report of 2011 [1]. However, the
most recent Tanzania HIV and malaria indicator surveys
(THMIS) conducted in 2011/2012 have shown that malaria
parasite prevalence has declined by >50% since the latest
surveys of 2007 (from 18% to 9%), with the highest parasite
prevalence of 33% in the North-western region of Geita
near Lake Victoria and the lowest of <1% in several re-
gions of North-western, Central, Southern highlands
and Zanzibar Island (MoH, unpublished data). Further-
more, studies conducted in Muheza district of north-
eastern Tanzania have showed a concurrent decline of
malaria incidence among hospitalized children, and interes-
tingly, also of community acquired bacteraemia, suggestingthat the decline in malaria burden is also affecting trends
of bacterial infections [26].
The data used in the WHO report [1] were derived from
hospital records through HMIS which in most cases are
over-estimated by including majority of patients diagnosed
based on symptoms only. Even in areas with the capacity
for malaria diagnosis by microscopy, previous studies
showed that malaria was commonly over-diagnosed espe-
cially in areas of low transmission, mainly attributed to
limited skills of microscopists for preparation and examin-
ation of blood smears [37]. Thus, more detailed studies
are required to determine the current malaria burden in
Tanzania particularly after introduction of malaria rapid
diagnostic tests (RDTs) in 2012.
Apart from the mentioned national surveys, the ob-
served decline in the burden of malaria in Tanzania is
based on few detailed studies [25-28] and thus, there is
limited information from other malaria endemic areas in
the country. Furthermore, the reasons for the decline of
malaria burden in these particular areas are not clear, al-
though some of the interventions deployed in recent
years are believed to be the main cause of the current
changes in malaria epidemiology [1,25,27]. This indicates
that more detailed studies are required to document the
trend of malaria in areas with variable endemicity and to
provide reliable information on the possible association
between interventions in place and resulting effects on
malaria burden, for supporting formulation of new pol-
icies for malaria control. Finally, the current decline in
the burden of malaria, when confirmed, will demand for
a significant changes in malaria control to identify and
treat the remaining cases and eventually attempt to
block malaria transmission as well as improve manage-
ment of non-malaria fevers.
A long-term presence in the two rural villages of Muheza
district enabled the present study to assess the long-term
trends of malaria burden over a period of 20 years (1992 –
2012). In these villages, which were until recently holo/
hyper-endemic to malaria, different inventions (including
ITNs, passive case detection and treatment of malaria, and
different anti-malarial drug trials) have been deployed,
reflecting changing local demands and national policies.
Their potential contribution to the observed trends of de-
creasing malaria is discussed, while the remarkable changes
of parasite prevalence are given in more details, including
differences between the two nearby villages.
Methods
Study site and interventions between 1992 and 2012
This study utilized assembled data collected during re-
peated cross-section surveys (CSS) conducted between
September 1992 and June 2012 in the village of Magoda
and between 1997 and June 2012 in the neighbouring vil-
lage of Mpapayu both in Muheza district in Tanga region,
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malaria and filariasis studies as described elsewhere
[38-40]. Currently, the two villages have a population of
2,934 individuals in 678 households and under-fives ac-
count for 13.2% of the entire population. The data gen-
erated by previous studies, therefore, provide additional
value in assessing the historical evidence to demonstrate
the impact of different interventions and policies over
the period.
After an initial screening of parasite prevalence of the
entire population of Magoda village in 1992, and based on
the promising results from the Gambia [41], a Maloprim®
(3.125 mg pyrimethamine and 25 mg dapsone, Glaxo-
SmithKline, UK) trial was the first study to be imple-
mented in Magoda in 1993–94 to test the prophylactic
effects of weekly administration of the drug on parasite in-
fections, anaemia and splenomegaly [40]. Children aged
<10 years old were given either one or two tablet(s) of
Maloprim® to under-fives and those aged 5–9 years, re-
spectively and followed-up weekly to determine their gen-
eral condition and malaria infection status [40]. Because of
increasing resistance to chloroquine (CQ) in Muheza dis-
trict which was then the government policy as first line
treatment of uncomplicated malaria [42], patients who de-
veloped parasitaemia during follow-up under this trial
were treated with either sulphadoxine/pyrimethamine (SP)
or amodiaquine (AQ) [40].
Subsequently, a mobile clinic, visiting Magoda village
twice weekly was introduced in 1994 to estimate if a re-
bound of malaria may arise after termination of the
Maloprim® trial, and the mobile clinic was continued till
November 2004 to provide medical services to the com-
munity. The mobile services and malaria monitoring
were extended to the neighbouring village of Mpapaya
from 1997. During the visits by the mobile clinic,
suspected cases of malaria had blood smears taken, and
treatment was given on clinical grounds using either SP
or AQ, because blood smears were only examined after
returning to the research laboratory, for practical rea-
sons. Patients not symptomatically treated but with
malaria parasites in blood smears, were given antimalar-
ials on the following day after microscopy results were
obtained. Furthermore, repeated in vivo drug efficacy
trials were carried out and involved patients with un-
complicated malaria (confirmed by microscopy) in
1994–1996 [43-45], 1997 [46] and 1998–1999 [38] test-
ing SP, and later AQ in 2003 [47]. In December 1998,
each sleeping bed in all households in Magoda (on re-
quest from the villagers), received a permethrin-treated
net (ITN) while in Mpapayu, deltamethrin-treated nets
were distributed in March 2001; all ITNs were re-
impregnated twice a year [38] until 2003. Throughout
the observation period (up to 2004), children and adults
with fever and other ailments requiring hospitalizationwere offered admission to the local designated district
hospital of Muheza located 10 km from the village. By
2005, a local dispensary was built to replace the mobile
clinic while artemisinin-combination therapy (ACT, with
artemether/lumefantrine, AL) was introduced in January
2007, following changes of malaria treatment policy [48];
and rapid diagnostic test for malaria (RDTs) were intro-
duced in 2012 (NMCP, Personal Communication).
Recruitment of participants and data collection
For this paper, complete data sets with personal details
which were recorded on a morbidity questionnaire in-
cluding age, sex and residence, parasite infection status
for asexual and sexual stages, haemoglobin (Hb) levels,
splenomegaly and ITN use and insecticide impregnation
status were available for CSS conducted between 1999
and 2012 (Table 1). Additionally, summarized data were
retrieved from reports covering the surveys conducted
in 1992 [49] and for other years (1995, 1996, 1997 and
1998), quarterly/annual reports of Amani Centre of the
National Institute for Medical Research (NIMR) were
used to get the prevalence and density of P. falciparum
infections. The CSS involved individuals aged between
six months and 20 years. The surveys were conducted
during (April/June) or after (July/September) the long
rain season between September 1992 and June 2012 as
described elsewhere [38,40,49,50].
Each recruited person was examined by a medical doc-
tor and had axillary temperature taken using a digital
thermometer, and splenomegaly was assessed as previ-
ously described [51]. Blood samples were collected from
each of the study participants by venous bleeding or
finger prick for parasitological examination and other
laboratory analyses. Thick and thin blood smears were
prepared and dried in the field, and later brought to the
laboratory for further processing. For the surveys
conducted before 2004, blood smears from participants
with fever (axillary temperature ≥37.5°C) were examined
after the end of each day and those with malaria para-
sites were treated with SP or AQ on the following day.
For the CSS conducted between 2008 and 2012, all par-
ticipants were tested with RDTs and those with positive
test results and other symptoms of uncomplicated mal-
aria were treated with AL as described by Ishengoma
et al. [50]. Asymptomatic individuals with positive RDT
results were not treated with anti-malarials, but were ad-
vised to report to the nearest dispensary in Magoda in
case they fell sick.
Laboratory analysis
Blood smears collected in the CSS were stained using
10% Giemsa solution for 30 minutes and examined at a
magnification of 1,000× to detect parasite species and
to determine parasitaemia. Quality control of results of
Table 1 Prevalence of P. falciparum gametocytes, splenomegaly and geometric mean gametocyte density among individuals who participated in malaria cross


















1999 383 (40.4) 38.6 12.1 31 232 (39.2) 40.5 22 40
2000 352 (27.8) 21.6 6 55 226 (34.5) 43.4 8 85
2001 352 (42.4) 45.6 7.8 95 202 (39.1) 52 5 62
2004 392 (36.0) 23.7 5.6 21 237 (38.7) 23.6 1.7 16
2008 422 (41.2) 0.7 5 32 268 (36.2) 1.6 2.2 49
2009 512 (33.4) 2.5 3.1 23 267 (38.2) 1.9 3 64
2010 480 (33.7) 0.2 0.4 121 273 (34.4) 1.1 0.7 22
2011 482 (26.6) 0.2 0.2 560 259 (28.2) 0.8 0 0
2012 459 (26.0) 0.7 0.4 52 252 (26.6) 0 0.4 32
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as described elsewhere [50,52]. Briefly, each blood smear
was examined by two technicians blinded of the patient
status and RDT results. Parasite density was calculated as
the average counts of the two technicians if their results
did not differ by more than 50% for blood smears with
≥400 asexual parasites/μl of blood. For blood smears with
< 400 asexual parasites/μl, any counts of each of the two
technicians was accepted and used to calculate the average
parasite density. Blood smears with discordant results
were re-examined by a third technician and the results of
any two technicians was accepted as explained above. Fur-
ther discordant smears were resolved by a team of three
technicians who re-examined such smears at the same
time. For the studies done between 1999 and 2004,
haemoglobin (Hb) levels were measured by PCV and later
converted into Hb levels (g/dl) as described elsewhere
[53]. In the CSS conducted from 2008 to 2012, Hb was
measured using a HemoCue (HemoCue, Ångelholm,
Sweden) and anaemia was described as Hb < 11 g/dl.
Ethical considerations
The studies which provided data for this paper were ap-
proved by the Medical Research Coordination Committee
of NIMR. Verbal and written informed consent was sought
from patients or parents/guardians in case of children. Vil-
lage meetings were held to explain and discuss the study
plans with community members and feedback including re-
sults of previous surveys was given to the communities
through the above meetings together with a written report.
Data analysis
Microsoft Access database was utilized for data manage-
ment with double entry, validation and cleaning of data col-
lected from 2008 to 2012; followed by analysis using
STATA version 11 (STATA Corp Inc., TX, USA). Data col-
lected in 1999–2004 were managed using Epi-Info (CDC,
Atlanta, USA) and Microsoft Excel, and later transferred to
STATA version 11 (STATA Corp Inc., TX, USA) for ana-
lysis. The analysis involved comparison of different variables
such as parasite positivity, parasite density, gametocyte
carriage, gametocyte density, splenomegaly, mean Hb, an-
aemia and ITN use in order to test for the differences
across years and between the two villages. Categorical data
were compared using chi-square test while continuous vari-
ables were tested using Students t-test. Logistic regression
analysis was used to assess the effects of different interven-
tions (using data collected from 1999 to 2012), such as de-
ployment and distribution of ITNs, anti-malarial drug trials
and changes of malaria treatment policy (chloroquine in
1999 – 2001, SP from 2001 to 2004 and AL in 2008 –
2012) on the risk of being infected with malaria parasites
after adjusting for age and fever status (if study participants
had fever or not). The different interventions which hadspecific point of deployment such as use of ITNs were
coded as binary variables and interventions which covered
a particular period were similarly labeled with reference to
the duration of such interventions; and these variables were
used in logistic regression analysis. Non-normal continuous
variables such as parasite density were log transformed to
normality. Linear regression models were used in modeling
the relationship between Hb concentration and parasite
density as response variables against explanatory variables.
P-value <0.05 was considered significant.
Results
Overall prevalence of P. falciparum infections in Magoda
(1992–2012) and Mpapayu village (1998–2012)
Although cross-sectional surveys (CSS) were conducted
in Magoda from 1992 to 2012, and in Mpapayu village
from 1998 to 2012 and involved individuals aged <20 years,
complete data (with demographic information, clinical,
parasitological and ITNs data) were only available for
CSS done between 1999 and 2012 (Table 1). For the
period between 1992 and 1998, summarized reports
were used to extract the prevalence and density of
P. falciparum infections obtained in those surveys. For
the nine CSS conducted in both villages between 1999
and 2012, a total of 6,050 individuals aged 0–19 years
(mean age = 7.8 ± SD 4.7 years) were enrolled (Table 1).
Children less than five years of age were 2,111 (34.9%),
and 2,984 (49.3%) were males.
In Magoda village studied over twenty years from1992
to 2012, the prevalence of P. falciparum infections in all
individuals below 20 years of age was 83.5% in 1992 and
88.0% in 1995; with a decline to 62.2% in 1996. This was
followed by a slight increase between 1996 and 1997, and
a steep decline from 1999 to 2004 (from 67.9% to 34.4%,
p < 0.001) (Figure 1). Between 2004 and 2008, a significant
increase in P. falciparum prevalence occurred (34.4 to
44.0%, p = 0.006), followed by a steep and steady decline
to 7.2% in 2012. In the village of Mpapayu, the highest
prevalence of P. falciparum infections was 81.5% in 1999
and it decreased significantly to 24.9% in 2004 (p < 0.001),
followed by a slight increase in 2008, and a steady decline
to less than 5% from 2011 onwards (Figure 1).
Comparison of the P. falciparum prevalence between
Magoda and Mpapayu villages (1999–2012)
The prevalence of P. falciparum was significantly
higher in Mpapayu compared to Magoda in 1999 and
2000 (p ≤ 0.002 for all comparisons) while for the CSS
conducted in 2004 and 2008 – 2012, the prevalence was
significantly higher in Magoda than Mpapayu village
(p ≤ 0.018) (Figure 1). After adjusting for the effects of
bed nets, age of study participants, fever status, changes in
malaria treatment guidelines and year of study (to account



























Figure 1 Overall prevalence of Plasmodium falciparum infections and interventions deployed in Magoda and Mpapayu villages in
Muheza district from 1992 to 2012.
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parasites decreased significantly by 75% between 1999 and
2004 and by 97% between 1999 and 2012 in Magoda vil-
lage; and by 89% and 99% in Mpapayu over the same
periods (p < 0.001, for all comparisons).
Age-specific prevalence of P. falciparum infections in
Magoda (1992 – 2012) and Mpapayu village (1999–2012)
In under-fives, the prevalence of P. falciparum infections
declined steadily over the years from 83.6% to 26% in
Magoda from 1992 – 2004, and 80% to 18.5% in Mpapayu
village between 1999 and 2004. Although the overall
prevalence did not change between 2004 and 2008 in both
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Figure 2 Age-specific prevalence of Plasmodium falciparum infections
and 2012. Confidence intervals were calculated by Wilson score method.17% to 0% between 2008 and 2012 in Magoda and
Mpapayu villages, respectively (Figure 2A and B). Between
the villages, the prevalence in under-fives was significantly
higher in Mpapayu compared to Magoda in 1999 (p =
0.003) and 2000 (p = 0.015), but was higher in Magoda
compared to Mpapayu in 2010.
For individuals aged ≥5 years from Magoda, the preva-
lence dropped from 91% to 39% between 1992 and 2004,
and then increased to 56.7% in 2008, followed by a
steady decline to 8.6% in 2012. A similar trend was ob-
served in Mpapayu village. However, the prevalence in
the same age group was significantly higher in Mpapayu
compared to Magoda in 1999 (p = 0.024) and 2000 (p =













in the villages of Magoda (A) and Mpapayu (B) between 1999
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After adjusting for the effect of the year of survey, the
decline in the prevalence of P. falciparum infections was
higher among under-fives compared to individuals aged
≥5 years in both villages (OR =1.97, 95% CI = 1.72 – 2.24;
p <0.001). When the analysis was performed by ca-
tegorizing study participants into three age groups (0–4,
5–9 and 10–19 years), the prevalence of P. falciparum
infections in both villages (Magoda and Mpapayu) de-
creased in all groups across the years with the lowest
prevalence observed in 2012. However, the peak parasite
prevalence which was observed in children aged 5–
9 years up to 2004 shifted to participants aged 10–
19 years from 2008 in Magoda and from 2009 onwards
in Mpapayu (Figure 2A and B).
Overall and age-specific geometric mean density of
P. falciparum infections in Magoda and Mpapayu
villages (1999–2012)
In Magoda, the geometric mean parasite density was
similar in the surveys conducted between 1999 and 2004
while a significant increase occurred between 2004 and
2008 (p = 0.004); followed by similar parasite density in
2008–2011, and a significant decline in 2012 (p < 0.001).
For Mpapayu, the parasite density was similar in 1999 –
2000, followed by a significant decline between 2001 and
2004 (p = 0.008) and a significant increase which was ob-
served between 2004 and 2008 (p = 0.041). The parasite
density was similar for the surveys conducted between
2008 and 2011 in Mpapayu, followed by a significant
decline in 2012 (p = 0.004) as also observed in Magoda.
The age-specific geometric mean parasite density was




























































Figure 3 Age-specific geometric mean of Plasmodium falciparum den
Mpapayu (B) between 1999 and 2012. Data of under-fives from Mpapay
because individuals seen were few and had high parasite density (4 with g
31,200 asexual parasites/μl, respectively). In Mpapayu, no study participantranged from 107 to 2,093 asexual parasites/μl in Magoda,
and 0 to 2,062 asexual parasites/μl in Mpapayu (Figure 3A
and B). Data of under-fives from Mpapayu village in 2010
and 2011 were excluded from the analysis and Figure 3B,
because individuals seen were few and had abnormally
high parasite density (4 with geometric mean parasite
density of 21,744 and one participant with 31,200 asexual
parasites/μl, respectively). Generally, individuals in all age
groups had higher parasite densities in 2008–2011 in
Magoda and 2008–2009 in Mpapayu compared to previous
CSS and those done in 2012 (Figure 3A and B).
Mean haemoglobin levels and anaemia in Magoda and
Mpapayu villages (1998–2012)
Complete data of haemoglobin levels (Hb, g/dl) were
available in under-fives only for the CSS conducted from
1998 to 2000, and between 2008 and 2012. For CSS
conducted between 1998 and 2000 in both villages, lin-
ear regression model adjusted for the effect of age, gen-
der and parasite density showed that the mean Hb was
increasing across the year by 0.18 (95% CI: 0.04 - 0.32),
p = 0.011, where the baseline mean Hb concentration
was 10.20 g/dl (95% CI: 9.97 -10.41). Between 2008 and
2012, there was an insignificant decrease in mean Hb by
0.03 (95% CI = −0.09 - 0.02), p = 0.237).
Prevalence of splenomegaly in Magoda and Mpapayu
villages (1999 – 2012)
The prevalence of splenomegaly in all age groups was
higher in the CSS conducted before 2004 with signifi-
cantly lower prevalence in the CSS conducted from 2008
onwards (2004 Vs 2008; χ2 = 156.7, p < 0.001). In Magoda








































sity (asexual parasites/μl) in the villages of Magoda (A) and
u village (B) in 2010 and 2011 were excluded from the analysis
eometric mean parasite density of 21,744 and one participant with
aged <5 years old had malaria parasites in 2012.
A = Magoda and B = Mpapayu village 





























































Figure 4 Proportion of under-fives and study participants
aged ≥5 years who reported to have slept under bed nets in the
past 24 hours before the survey in the villages of Magoda (A) and
Mpapayu (B) in Muheza district between 1999 and 2012.
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in 2004 when it was significantly higher in under-fives
(p = 0.001) (see Table 1). Mpapayu village had higher
prevalence of splenomegaly than Magoda in most years
with significantly higher prevalence in under-fives
(p < 0.043) in 1999, 2000 and 2012, while it was signifi-
cantly higher in those aged ≥5 years in 2004 only
(χ2 = 11.4, p = 0034). The prevalence of splenomegaly
among under-fives was significantly higher in Mpapayu
compared to Magoda in 1999 (p = 0.006) and 2000
(p < 0.001) only, while in those aged ≥5 years, the preva-
lence was higher in Mpapayu in 2000 only (p < 0.001). In
all age groups, the highest prevalence of splenomegaly
(52.0%) was observed in Mpapayu village in 2001.
Gametocyte prevalence and density in Magoda and
Mpapayu villages (1999 – 2012)
Gametocyte prevalence in all age groups were lower in
the surveys conducted from 2008–2010 compared to
those conducted before 2004 and it decreased signifi-
cantly over the study period (χ2 for trend = 228.3,
p < 0.001). When the two villages were compared, the
prevalence was significantly higher in Mpapayu than
Magoda in 1999 (p < 0.001), and in Magoda than
Mpapayu in 2004 (p = 0.017) (Table 1). From 2008 to
2012, few individuals (≤5%) carried gametocytes whereby
only one and two individuals from Magoda village had
gametocytes in 2011and 2012, respectively. In Mpapayu,
no gametocytes were detected in 2011 while only one
individual had gametocytes in 2012.
Bed net usage in Magoda and Mpapayu villages between
1999 and 2012
The proportion of individuals who reported to have slept
under bed nets a night before the survey (whether impreg-
nated with insecticides or not) was higher in the CSS of
1999 – 2004 than those of 2008–2012, with usage >88% in
Magoda between 1999 and 2004 and >90% in Mpapayu
between 2001 and 2004 (Figure 4A and B). In Magoda
village, individuals (all age groups) using bed nets in
2008 had decreased to ≤45.0% followed by an increase
to ≥54.0% in 2009 (Figure 4A). In Mpapayu, very few
individuals (<4%) were using bed nets before free ITNs
were distributed to all people in 2001. However, the
number of individuals using bed nets in Mpapayu
increased to ≥85% by 2004 and later decreased to <74%
in 2008, and continued to decline reaching the lowest
number of users in 2011 (35.0% among individuals aged
≥5 years). In 2012, the number of bed net users increased
to over 64.0% in both villages following a national
campaign of universal bed net coverage (Figure 4A and B).
For the two villages and in all age groups, there were
significantly higher bed net usage in Magoda village than
Mpapayu in 1999 and 2000 (p < 0.001) while the numberof bed net users was significantly higher in Mpapayu in
2008 and 2010 (p < 0.001). The risk of being infected by
malaria parasites was significantly higher among individ-
uals not using bed nets in both villages, after adjusting for
age, fever status and year of study (Magoda, OR = 1.22,
p = 0.044 and in Mpapayu, OR = 1.59, p = 0.003). Over the
years, individuals using bed nets in both villages had lower
risk of carrying malaria parasites, e.g. by <45% in 2000 and
decreased by >97% between 1999 and 2012 (p < 0.001 for
all comparisons).
Discussion
Although the information on the current burden of malaria
in most of the malaria endemic countries is fragmented or
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has declined in some endemic countries [2]. For Tanzania,
a significant decline of malaria burden has been con-
firmed on the islands of Zanzibar after deployment of
intensive malaria interventions including ACT, ITNs
and IRS [16,17], whereas data on the changing epi-
demiology of malaria on the mainland are less well
documented and relatively few reports exist except
from some parts including north-eastern Tanzania.
Furthermore, previous [28] and the most recent
Tanzania HIV and malaria indicator surveys (THMIS)
of 2011/2012 showed a significant decline of malaria
burden, whereby the average parasite prevalence in
under-fives decreased from 18% to 9% between 2007
and 2011 (MoH, unpublished data). These nation-wide
surveys are aggregated at the regional level and cannot
give detailed patterns of malaria at small geographic
coverage such as the district.
Studies of malaria (and other parasitic diseases, such
as lymphatic filariasis) including repeated cross-sectional
studies were conducted in the villages of Magoda (since
1992) and Mpapayu (since 1997) in Muheza district of
north-eastern Tanzania and have enabled long-term ob-
servations of trends in malaria for over 15–20 years. The
studies also showed the possible impact of the deployed
interventions at the community level and changing na-
tional malaria control policies. These villages and other
parts of Muheza have been reported to have high burden
of malaria, as well as high levels of resistance to different
anti-malarial drugs [43-47]. Treatment-wise, in Magoda
village, SP and AQ were deployed early in 1994 during
the Maloprim® trial [40], and CQ was withdrawn (due to
high level of resistance) even before the official change
of malaria treatment policy replacing CQ with SP were
effected in 2001 [54].
Overall, the study reported here observed a significant
decline of malaria burden over the study period. Although
the major decline in the prevalence of P. falciparum infec-
tions occurred between 1997 and 2004 (Magoda) and
1998–2004 (Mpapayu) when more interventions were be-
ing implemented, further changes were also observed
between 2008 and 2012 in both villages. The peak preva-
lence of malaria shifted from children aged 5–9 to those
aged 10–19 years old in 2008–2012, a trend also observed
in the highlands of the neighbouring district of Korogwe
which generally have low malaria transmission [51]. The
prevalence of splenomegaly and gametocytes also declined
during the same period.
The decline in prevalence observed before 1999 could
possibly be due to better services provided by the re-
search team while the changes observed between 1999
and 2004 could also be attributed to drug trials, which
were implemented from 1994 [43-47], and later deploy-
ment of free ITNs [38]. During these trials, the researchteams were always available in the communities and
provided health services to other patients including
treatment of malaria, regardless of their involvement in
the studies. The deployment of ITNs at different time
points in the two villages, while other services were
otherwise equal, enabled an estimation of the impact of
ITNs on malaria and prevalence of drug resistance
markers [38]. High bed net coverage has also been asso-
ciated with reduced malaria morbidity and mortality as
reported in previous studies [55,56].
Presence of research team in the villages, deployment
of a mobile clinic and other services provided by village
health workers would also possibly reduce malaria bur-
den through prompt diagnosis and treatment and refer-
ral to Muheza district hospital for free services, when
needed. Furthermore, the records collected between
1992 and 2004 showed that the number of deaths
declined significantly and cerebral malaria virtually
disappeared from Magoda and Mpapayu village (Ib C.
Bygbjerg, personal communication). Similar studies
conducted in the neighbouring district of Korogwe also
showed that improved health services at the community
level through deployment and use of village health
workers under the supervision of trained medical
personnel was associated with a significant reduction in
the burden of malaria [25,27]. Although each of the in-
terventions deployed during the aforementioned period
might be attributed to the reduction in malaria burden
observed by 2004, the contribution of each of the inter-
ventions implemented could not be fully quantified by
this study.
In the CSS conducted in 2008 – 2012, the prevalence of
P. falciparum infections dropped to <10% in Magoda and
<5% in Mpapayu from 2011. Of the recent interventions,
AL was introduced as first-line drug for treatment of
uncomplicated malaria in January 2007and free ITNs
were distributed in Magoda in 2009 through the US
President Malaria Initiative (US PMI), followed by
long-lasting nets in 2012 (Zuberi Mohamedi, personal
communication). However, the coverage and usage
of bed nets remained below 74%, i.e. far below the
levels attained by 2004. It is thought-provoking that
coverage and use of ITNs were much higher before
2004, when ITNs were distributed by the project
compared to the most recent coverage under the na-
tional universal campaigns. Factors other than ITNs and
deployment of AL could possibly be driving the most
recent changes as also reported by Okiro et al. [34]. These
include changes in climatic variables, such as rainfall and
temperature, improvements of socio-economic status,
health care and human land use activities, which could pos-
sibly be associated with declining malaria transmission.
However, such factors were not assessed in this study and
are worth taking into account in future studies.
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intensity such as the prevalence of splenomegaly and
gametocytes indicate that these areas formerly known
as holo/hyper-endemic have now become low malaria
transmission settings within very few years as also re-
cently shown in the neighbouring district of Korogwe
[25,27]. The shift of parasite prevalence to older children
and adolescents in 2008–2012 might be attributed to de-
layed development of immunity among study partici-
pants due to reduced exposure to infections [57,58].
The significant decline in the prevalence of P. falcip-
arum gametocytes observed in the CSS done between
2008 and 2012 could partly be attributed to the effects
of ACT together with ITNs which reduce malaria
transmission. Previous studies have shown that arte-
misinins reduce the parasite biomass drastically and
thus reducing the rate of development and gametocyte
carriage [59]. Such effects could be responsible for
the low prevalence of gametocytes in the study areas
observed in the recent CSS. Despite an increase in
mean Hb levels and a decrease in the prevalence of an-
aemia before 2000, there were no significant changes
over the study period. However, a slight increase in mean
Hb and a decline in the prevalence of anaemia were ob-
served in 2012 which could possibly indicate that there
was a slight lag between the decline of malaria prevalence
and downward trends of anaemia in these communities.
Further monitoring will be crucial to document these im-
portant changes in malaria prevalence and their influence
on other malariometric indices.
Although vector population studies have not been done
in the study villages in recent years, studies conducted in
the neighbouring villages in Muheza and Tanga districts
showed that the density of malaria vectors has progres-
sively declined leading to low transmission in this part of
the country [60]. Furthermore, the composition of malaria
vector populations in Muheza has significantly changed
whereby the anthropophilic Anopheles gambiae s.s. have
been replaced with the zoophilic Anopheles arabiensis
[61]. These studies suggest that the changes in vector
density and composition could be responsible for the low
malaria burden in the area and other parts of Tanzania as
recently revealed by the nation – wide malaria indicator
surveys of 2011(MoH, Unpublished data). Thus, the ob-
served trends of declining malaria burden could be linked
to the interventions deployed in the study communities
including ITNs, drug trials, better health care through mo-
bile clinic, changing national malaria control policies and
other unknown factors which could have indirectly caused
the dramatic reduction in malaria transmission. However,
the low burden of malaria observed in these villages can-
not be generalised to reflect the situation in other parts of
Tanzania due to high level of interventions which were
deployed in the area over the study period.Conclusion
This study showed a marked decline of malaria burden in
the study area between 1992 and 2012, initially between
1992 and 1996, and a further decline from 2008 to 2012.
The decline in the initial period (1992 – 2004) was associ-
ated with the deployment of different interventions such
as a weekly mobile clinic, bed nets and other research ac-
tivities. However, the dramatic and steady decline ob-
served from 2008 occurred when bed net coverage was
much lower, suggesting that other factors such as intro-
duction of ACT could also have contributed to the most
recent changes. A shift of parasite prevalence from youn-
ger to older children/adolescents and increasing parasite
density until 2011 imply that the transmission intensity
has significantly declined leading to delayed development
and low immunity among residents of these villages,
making these areas which were holo/hyperendemic to
become epidemics-prone or unstable malaria transmis-
sion. Further monitoring of malaria burden in these and
other communities will potentially reveal future trends
of malaria transmission and identify other factors which
could be responsible for these significant changes of
malaria epidemiology in order to appropriately devise
new control strategies. The significant reduction in
transmission implies the need for strengthening of the
routine surveillance system and introduction of stratifi-
cation to ensure that the fewer cases are captured and
treated and apply focused intervention. These results
also provide evidence that could be used in monitoring
the progress of health related millennium development
goals (MDGs).
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